Ravulizumab

證據等級: L5

預測適應症: 10 個

Ravulizumab: From Complement-Mediated Diseases (PNH/aHUS) to G6PC3-Deficient Congenital Neutropenia

One-Sentence Summary

Ravulizumab is a long-acting anti-complement C5 monoclonal antibody, with established use in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The TxGNN model predicts it may be effective for autosomal recessive severe congenital neutropenia due to G6PC3 deficiency, but this is currently a model prediction only — no clinical trials or published literature support this direction, and the evidence pack's own mechanistic review flags the biological rationale as weak.

Quick Overview

Item	Content
Original Indication	Not on file in Taiwan regulatory data; per the mechanistic rationale, ravulizumab's established use is in complement-mediated diseases (PNH, aHUS)
Predicted New Indication	Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency
TxGNN Prediction Score	99.96% (model rank 731)
Evidence Level	L5
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ravulizumab is not available in this evidence pack (flagged as a High-severity data gap). Based on known information referenced in the model's own rationale, ravulizumab is a long-acting anti-C5 monoclonal antibody that blocks the terminal complement pathway (membrane attack complex formation); its efficacy in complement-driven diseases such as PNH and aHUS is well established.

G6PC3-deficient congenital neutropenia, however, is caused by glucose-6-phosphatase catalytic subunit 3 deficiency, which increases endoplasmic reticulum stress and apoptosis in neutrophil precursors through a glucose/glycosylation metabolic defect — a pathway that does not intersect with terminal complement activation. The evidence pack explicitly notes there is no direct mechanistic link between the two conditions, and characterizes this prediction as a similarity-based extrapolation by TxGNN across a broad "rare hematologic/immune disease" category rather than a validated pathophysiological connection.

Given this, the prediction should be read as a hypothesis-generating signal rather than a mechanistically grounded repurposing candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Ravulizumab currently holds no marketing authorization on file for this region (0 licenses; market status: 未上市 / not marketed), so no product-level licensing details are available.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack; a TFDA package insert lookup is flagged as a Blocking data gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical, preclinical, or literature evidence for this indication, and the model's own mechanistic review found no direct pathway linking C5/complement inhibition to G6PC3-deficient neutropenia — the association is a category-level similarity extrapolation, not a validated hypothesis.

To proceed, the following is needed:

TFDA/regulatory package insert (warnings, contraindications) — currently a Blocking gap
Confirmed mechanism of action data from DrugBank or primary literature
Preclinical or mechanistic studies directly testing complement pathway involvement in G6PC3-deficient neutropenia
Real-world or trial-registry evidence (ClinicalTrials.gov, ICTRP) before advancing past S0
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.